Frontiers in Microbiology · 2022 · 14 citations · 24 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMedical MicrobiologyMicrobial PathogenesisAntibacterial ResistanceAntibacterial TherapyAntibiotic ResistanceAntimicrobial TherapyCarbapenem ResistanceFecal Microbiota TransplantationAntibiotic-resistant Pathogen ControlBacterial Lipopolysaccharide RecognitionDrug-resistant PathogensIntestinal Microbiota EffectsIntestinal Microbiota EstablishmentKlebsiella Pneumoniae CarbapenemaseKlebsiella Pneumoniae ResistanceTreatment Of Bacterial Resistance
Background Klebsiella pneumoniae is a normal component of the human gastrointestinal tract microbiota. However, in some cases, it can cause disease. Over the past 20 years, the prevalence of antibiotic-resistant bacteria, such as carbapenem-resistant K. pneumoniae (CRKP), has been increasing. Materials and methods We attempted to specifically eliminate CRKP from a mouse model with the human intestinal microbiota. To establish humanized microbiota-colonized mice, we administered K64 CRKP-containing human microbiota to germ-free mice by fecal microbiota transplantation. Then, we used two phages, one targeting the capsule (φK64-1) and one targeting O1 lipopolysaccharide (φKO1-1) of K64 K. pneumoniae , to eliminate CRKP. Results In untreated control and φKO1-1-treated K64-colonized mice, no change in CRKP was observed, while in mice treated with φK64-1, a transient reduction was observed. In half of the mice treated with both φKO1-1 and φK64-1, CRKP was undetectable in feces by PCR and culture for 60 days. However, in the other 50% of the mice, K. pneumoniae was transiently reduced but recovered 35 days after treatment. Conclusion Combination treatment with φK64-1 and φKO1-1 achieved long-term decolonization in 52.3% of mice carrying CRKP. Importantly, the composition of the intestinal microbiota was not altered after phage treatment. Therefore, this strategy may be useful not only for eradicating drug-resistant bacterial species from the intestinal microbiota but also for the treatment of other dysbiosis-associated diseases.
24
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jínek, Krzysztof Chylinski, Ines Fonfara et al. · Science · 2012 · 17.3K citations · Full text
Alicia Hidrón, Jonathan R. Edwards, Jean B. Patel et al. · Infection Control and Hospital Epidemiology · 2008 · 3.8K citations
Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis
Jethro S. Johnson, Daniel Spakowicz, Bo‐Young Hong et al. · Nature Communications · 2019 · 2.3K citations · Full text
Life Sciences, Biology, Microbiology +14
Chi‐Tai Fang, Yi‐Ping Chuang, Chia‐Tung Shun et al. · The Journal of Experimental Medicine · 2004 · 770 citations · Full text